IRMD

IRadimed Corp. reported record revenue for Q4 2025 and Q1 2026, along with record GAAP diluted EPS. A special cash dividend was approved, and the regular quarterly cash dividend was increased. The commercial launch of the next-generation 3870 MRI-compatible IV infusion pump system occurred in Q1 2026. The company reaffirmed its full-year 2026 revenue and GAAP diluted EPS guidance. IRadimed participated in the 38th Annual Roth Conference and the 25th Annual Needham Virtual Healthcare Conference. The stock experienced a decline in the 30 and 90 days leading up to May 6, 2026, despite a strong 1-year total shareholder return.